Oncology’s New Disruptions
In preparation for the ACCC 46th Annual Meeting & Cancer Center Business Summit in Washington, D.C., we are talking with several featured speakers about the topics they plan to address at the summit.
Related Articles
The State of MCED Screening and the Science Behind the Innovation | LinkedIn
Join us for an engaging 1-hour discussion with leading experts on the cutting edge science and current state of multi-cancer early detection (MCED) screening. Discover…
The State of MCED Screening and the Science Behind the Innovation | LinkedIn
Join us for an engaging 1-hour discussion with leading experts on the cutting edge science and current state of multi-cancer early detection (MCED) screening. Discover…
Clinical Trials: A Critical Component of Pancreatic Cancer Care
Instead of viewing clinical trials as a last resort, patients with pancreatic cancer and their oncologists are encouraged to investigate clinical trials from the start…
Highlighting the Importance of the Multidisciplinary Care Team in Skin Cancer Care
One of the best things health care providers can do for patients with non-melanoma skin cancer is coordinate treatment via multidisciplinary teams to determine the…
Establishing Goals of Treatment in Relapsed/Refractory Mantle Cell Lymphoma – [Video Podcast] Ep 51
In this episode, CANCER BUZZ speaks with Jeff Sharman, MD about the role of biomarker testing in guiding treatment decisions and how evidence-based management of…
NOC Preview: Developing a Health Equity Playbook
When developing a health equity playbook, cancer programs need to break down existing silos and ensure that all key players are involved in developing strategies…
2024 Trending Now in Cancer Care Part 2 | Oncology Issues
Can’t sign in? Forgot your username? Can’t sign in? Forgot your password? Oncology Issues, 2024;39(4):24–49 From 2010 to 2019, the Association of Cancer Care Centers…
Somatic Profiling Prospectively Guides Germline Genetic Testing in Patients with Mutations in High-Risk Cancer Predisposition Genes | Oncology Issues
In Brief: While approximately 15% of patients with advanced cancer have an inherited predisposition to malignancy, many patients who carry a pathogenic germline variant do…